Necrotizing Enterocolitis Market Report 2025

The necrotizing enterocolitis market size has grown strongly in recent years. It will grow from $4.83 billion in 2024 to $5.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historic period can be attributed to factors such as the rising incidence of necrotizing enterocolitis, growing populations, higher per capita income, increased government funding, and a rise in premature births.

The necrotizing enterocolitis market size is expected to see strong growth in the next few years. It will grow to $6.62 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Looking ahead, the growth during the forecast period can be driven by factors such as increasing healthcare costs, the rising incidence and prevalence of ulcerative colitis (UC), the growing number of gastrointestinal diseases, the increase in geriatric and obese populations, and the expanding elderly demographic. Key trends expected in the forecast period include advancements in biomarker research for early NEC detection, progress in non-invasive testing methods, adoption of advanced monitoring systems, improvements in surgical techniques, and the development of targeted therapies.

The rising number of premature births is expected to drive the growth of the necrotizing enterocolitis (NEC) market. Premature births, or preterm births, occur when a baby is delivered before 37 weeks of gestation, compared to the typical 40-week term. The increase in premature births is attributed to maternal health conditions such as high blood pressure, diabetes, and infections, which elevate the risk of preterm labor, as well as lifestyle factors such as smoking, drug use, and poor nutrition. Premature infants are more vulnerable to necrotizing enterocolitis because their gastrointestinal systems are underdeveloped, making them more susceptible to inflammation and infection. For example, in January 2024, the Centers for Disease Control and Prevention reported that premature births account for 8.67% of all births in the U.S. annually. As a result, the rise in premature births is contributing to the growth of the NEC market.

Companies in the necrotizing enterocolitis market are focusing on developing innovative treatments to address the critical unmet needs for effective therapies in premature infants. One such solution is cell-free sterile biologic solutions, which are purified, sterile liquids containing bioactive molecules such as proteins, growth factors, and cytokines derived from cultured cells but without intact cells. These biologic solutions are designed to promote healing and reduce inflammation. For instance, in December 2023, Noveome Biotherapeutics, Inc., a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration to proceed with a Phase 1-2 clinical trial for ST266, a novel biologic targeting NEC in premature infants. This marks a significant advancement, as ST266 is expected to be the first major therapeutic development for NEC in over three decades, addressing a critical need given the high morbidity and mortality rates associated with the disease among vulnerable populations.

In January 2025, Siolta Therapeutics, a U.S.-based developer of novel live biotherapeutics for NEC, partnered with Cowellnex Co. to combat the disease in premature infants. This collaboration combines Siolta’s expertise in microbial science with Cowellnex’s strength in microbiome drug discovery. By leveraging Siolta's Precision Symbiotics Platform, the partnership aims to advance research and develop treatments for NEC in premature infants. Cowellnex Co. Ltd. is a biotechnology company focused on advancing microbiome drug discovery.

Major players in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children's Hospital, Hollister Incorporated, UPMC Children's Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in necrotizing enterocolitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the necrotizing enterocolitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Necrotizing enterocolitis (NEC) is a severe, potentially life-threatening gastrointestinal disorder that primarily affects premature infants. It is characterized by inflammation and tissue death (necrosis) in the intestines, which can lead to complications such as perforation and infection. Common symptoms of NEC include feeding intolerance, abdominal bloating, vomiting, and changes in bowel movements.

The primary treatment options for necrotizing enterocolitis include total parenteral nutrition (TPN), gastrointestinal decompression, antimicrobial therapy, antifungal treatment, paracentesis, and other interventions. TPN provides essential nutrients directly into the bloodstream, allowing the intestines to rest and heal, which is particularly beneficial for infants with NEC. Diagnosis involves various laboratory tests and imaging techniques across multiple stages stage I (suspected NEC), stage II (definite NEC), and stage III (advanced NEC). These treatments are distributed through several channels, such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and more, and are used in settings such as hospitals, neonatal intensive care units (NICUs), and specialty clinics.

The necrotizing enterocolitis market research report is one of a series of new reports that provides necrotizing enterocolitis market statistics, including the necrotizing enterocolitis industry global market size, regional shares, competitors with the necrotizing enterocolitis market share, detailed necrotizing enterocolitis market segments, market trends, and opportunities, and any further data you may need to thrive in the necrotizing enterocolitis industry. This necrotizing enterocolitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The necrotizing enterocolitis market consists of revenues earned by entities providing services such as neonatal intensive care, nutritional support, medical monitoring and support, and parental counseling and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrotizing enterocolitis market also includes sales of feeding tubes, surgical instruments for resection, and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.